V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Academic Article uri icon

Overview

abstract

  • The Raf family includes three members, of which B-Raf is frequently mutated in melanoma and other tumors. We show that Raf-1 and A-Raf require Hsp90 for stability, whereas B-Raf does not. In contrast, mutated, activated B-Raf binds to an Hsp90-cdc37 complex, which is required for its stability and function. Exposure of melanoma cells and tumors to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in the degradation of mutant B-Raf, inhibition of mitogen-activated protein kinase activation and cell proliferation, induction of apoptosis, and antitumor activity. These data suggest that activated mutated B-Raf proteins are incompetent for folding in the absence of Hsp90, thus suggesting that the chaperone is required for the clonal evolution of melanomas and other tumors that depend on this mutation. Hsp90 inhibition represents a therapeutic strategy for the treatment of melanoma.

publication date

  • December 21, 2005

Research

keywords

  • Cell Cycle Proteins
  • Chaperonins
  • Gene Expression Regulation, Neoplastic
  • Melanoma
  • Mutation, Missense
  • Proto-Oncogene Proteins B-raf

Identity

PubMed Central ID

  • PMC1325013

Scopus Document Identifier

  • 30444441778

Digital Object Identifier (DOI)

  • 10.1073/pnas.0609973103

PubMed ID

  • 16371460

Additional Document Info

volume

  • 103

issue

  • 1